High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion

Z. R. Zeigler, R. K. Shadduck, C. S. Rosenfeld, K. F. Mangan, A. Winkelstein, A. Oral, G. E. Ramsey, R. J. Duquesnoy

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Ten patients, with bone marrow failure or malignant disorders, became refractory to platelet transfusions using random, as well as partial or fully HLA-matched, single-donor platelets. To determine its effect on platelet refractoriness, intravenous gamma globulin (IV IgG) was administered at 400 or 800 mg/kg/d for five days, and postinfusion platelet responses were monitored. Platelet transfusion responses following intravenous gamma globulin (IV I96) were graded as follows: Excellent, 48-hour posttransfusion count > 50,000/μL; good, 48-hour count > 20,000 but <50,000/μL; Fair, increased increment, 48-hour count <20,000; and failed, no increased increment. Six of ten patients (60%) had improved responses to selected single-donor platelets (two were excellent, three were good, and one was fair). The time to achieve a platelet transfusion count > 25,000/μL ranged from one to nine days of IgG therapy. One individual had sustained benefit (> 1 year); the remaining responses persisted for 6 to 8 weeks. These results suggest that IV IgG may be useful in the management of platelet refractoriness, especially in patients receiving single-donor platelets.

Original languageEnglish (US)
Pages (from-to)1433-1436
Number of pages4
JournalBlood
Volume70
Issue number5
DOIs
StatePublished - 1987

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion'. Together they form a unique fingerprint.

Cite this